Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03819647
Other study ID # HYPOP (STP194)
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date May 21, 2019
Est. completion date March 8, 2021

Study information

Verified date November 2020
Source Biocodex
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Evaluation of the efficacy of stiripentol (Diacomit) as monotherapy for the treatment of primary hyperoxaluria. Pilot clinical study, open, prospective and multicenter.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date March 8, 2021
Est. primary completion date December 18, 2020
Accepts healthy volunteers No
Gender All
Age group 6 Months and older
Eligibility Inclusion Criteria: - Patient with primary hyperoxaluria type 1, 2 or 3, diagnosed according to standard methods - Having at least one molar ratio [oxaluria / creatinuria] greater than 0.08 since diagnosis - Having Glomerular Filtration Rate = 45 mL / min / 1.73m2 - Age = 6 months - Having read, or whose parents have read, the information note and signed the consent form. For children, if their level of understanding allows, their assent will also be sought - Proficient enough, or whose parents or legal representatives have sufficient mastery, the French language to read, understand and complete study documents - Affiliate or beneficiary of a social security scheme - Ability to respect the protocol, including treatment, and can be followed regularly in the study - For pubertal patients, contraception deemed effective by the investigator or abstinence Exclusion Criteria: - Introduction, discontinuation or dose modification of vitamin B6 or potassium citrate treatment within 4 weeks prior to the inclusion visit - Consumption of jelly candies and / or dark chocolate in the week preceding the study - Patient having a kidney and / or liver transplant - Presence of a clinically significant acute or chronic pathology, other than primary hyperoxaluria, that may interfere with the evaluation of the study results according to the investigator - During biological or physical examinations, presence of significant anomaly (s) inconsistent with participation in the study according to the investigator - History of severe allergy, asthma, skin rash or hypersensitivity to a drug - Treatment affecting hepatic metabolism (cimetidine, ketoconazole, fluconazole, itraconazole, phenytoin, rifampicin, rifabutin) in progress or taken during the month preceding the start of the study - Treatment affecting the renal tubule (probenecid, ß-lactams, ...) in progress or taken during the last two weeks preceding the start of the study - Presence of a pathology or treatment that, according to the investigator, renders the subject unfit - Contraindications to stiripentol as defined in the current SmPC (hypersensitivity to the active substance or to any of the excipients listed in section 6.1 of the SmPC, history of psychosis in the form of delusional episodes) - Pregnant or lactating woman - Patient under guardianship - Patient concurrently participating in another clinical trial or exclusion period following a previous trial

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
stiripentol (Diacomit)
Administration of stiripentol per os

Locations

Country Name City State
France Hôpital Necker Paris
France Hôpital Robert Debré Paris
France Hôpital Tenon Paris

Sponsors (1)

Lead Sponsor Collaborator
Biocodex

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Relative variation (%) of the molar ratio [oxaluria / creatinuria] between baseline and after two weeks of treatment. Relative variation (%) of the molar ratio [oxaluria / creatinuria] between baseline and after two weeks of treatment. Change (%) of the molar ratio [oxaluria / creatinuria] between the baseline value (average of 3 measures done during pre-treatment period) and the value (average of 2 measures) after 2 weeks of treatment.
Primary Relative variation (%) of the molar ratio [oxaluria / creatinuria] between baseline and after three weeks of treatment. Relative variation (%) of the molar ratio [oxaluria / creatinuria] between baseline and after three weeks of treatment. Change (%) of the molar ratio [oxaluria / creatinuria] between the baseline value (average of 3 measures done during pre-treatment period) and the value (average of 2 measures) after 3 weeks of treatment.
Secondary Response to treatment defined by a decrease> 20% of the molar ratio [oxaluria / creatinuria] Response to treatment defined by a decrease> 20% of the molar ratio [oxaluria / creatinuria] 3 measures from inclusion to first treatment intake (= baseline value), then 2 measures at Day 14 and Day 15 respectively (=value after 2 weeks of treatment), and 2 measures at Day 20 and Day 21 respectively (=value after 3 weeks of treatment)
Secondary Relative variation (%) of supersaturation of urine with calcium oxalate between the start and the end of treatment period Relative variation (%) of supersaturation of urine with calcium oxalate between the start and the end of treatment period 3 measures from inclusion to first treatment intake (= baseline value), then 2 measures at Day 14 and Day 15 respectively (=value after 2 weeks of treatment), and 2 measures at Day 20 and Day 21 respectively (=value after 3 weeks of treatment)
Secondary Relative variation (%) in overall crystalline volume measured by crystalluria on fresh urine between the start and the end of treatment period Relative variation (%) in overall crystalline volume measured by crystalluria on fresh urine between the start and the end of treatment period 3 measures from inclusion to first treatment intake (= baseline value), then 2 measures at Day 14 and Day 15 respectively (=value after 2 weeks of treatment), and 2 measures at Day 20 and Day 21 respectively (=value after 3 weeks of treatment)
Secondary Effect of stiripentol dose increase on absolute decrease of the molar ratio [oxaluria / creatinuria] Effect of stiripentol dose increase on absolute decrease of the molar ratio [oxaluria / creatinuria] 3 measures from inclusion to first treatment intake (= baseline value), then 2 measures at Day 14 and Day 15 respectively (=value after 2 weeks of treatment), and 2 measures at Day 20 and Day 21 respectively (=value after 3 weeks of treatment)
Secondary Effect of stiripentol dose increase on relative decrease (%) of the molar ratio [oxaluria / creatinuria] Effect of stiripentol dose increase on relative decrease (%) of the molar ratio [oxaluria / creatinuria] 3 measures from inclusion to first treatment intake (= baseline value), then 2 measures at Day 14 and Day 15 respectively (=value after 2 weeks of treatment), and 2 measures at Day 20 and Day 21 respectively (=value after 3 weeks of treatment)
Secondary Blood test results (hepatic assessment) at the start and at the end of the study Blood test results (hepatic assessment) at the start and at the end of the study From start of participation of the patient to end of the treatment period (up to 8 weeks)
Secondary Blood test results (blood cells count) at the start and at the end of the study Blood test results (blood cells count) at the start and at the end of the study From start of participation of the patient to end of the treatment period (up to 8 weeks)
Secondary Frequency and nature of the adverse events throughout the study Frequency and nature of the adverse events throughout the study From start of participation of the patient to end of the treatment period (up to 8 weeks)
See also
  Status Clinical Trial Phase
Withdrawn NCT00875823 - International Registry for Primary Hyperoxaluria N/A
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Completed NCT02340689 - Primary Hyperoxaluria Mutation Genotyping/Phenotyping
Completed NCT00638703 - Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria Patients Phase 2/Phase 3
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Recruiting NCT02026388 - Rare Kidney Stone Consortium Biobank
Completed NCT02000219 - Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Primary Hyperoxaluria Patients Who Are on Dialysis Phase 2
Recruiting NCT05843851 - Genetic Newborn Screening for Cystinosis and Primary Hyperoxaluria N/A
Recruiting NCT00588562 - Rare Kidney Stone Consortium Patient Registry
Completed NCT03391804 - Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia Phase 2
Completed NCT03116685 - A Study to Evaluate the Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria Phase 3
Recruiting NCT05107830 - Phenotyping of Primary Hyperoxaluria
Active, not recruiting NCT04152200 - A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 Phase 3
Recruiting NCT05001269 - Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function Phase 2
Completed NCT03392896 - Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria Phase 1
Completed NCT02012985 - Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Patients With Primary Hyperoxaluria Phase 1/Phase 2
Completed NCT01037231 - Phase 2/3 Oxabact Study Phase 2/Phase 3
Completed NCT00589225 - Primary Hyperoxaluria Mutation Genotyping Phase 1
Completed NCT02124395 - Health-related Quality of Life in Rare Kidney Stone
Completed NCT03350451 - An Extension Study of an Investigational Drug, Lumasiran (ALN-GO1), in Participants With Primary Hyperoxaluria Type 1 Phase 2